Incretin Trials Often Exceed Muscle-Loss Benchmarks - Takeaway - MDSpire
From the Journals
Conference News

Incretin Trials Often Exceed Muscle-Loss Benchmarks

Systematic review finds muscle-related losses frequently surpass expected thresholds during weight loss, though clinical impact remains unclear

Share

  • 1

    Systematic review of 36 trials on incretin therapies.

  • 2

    Led by Dr. John A. Batsis, UNC.

  • 3

    Muscle loss exceeded benchmarks in two-thirds of treatments.

  • 4

    Significant reduction in fat mass and visceral adipose tissue.

  • 5

    Lack of objective physical function outcomes reported.

  • 6

    Need for pairing treatments with exercise and protein intake emphasized.

  • 7

    Results presented at ACP Internal Medicine Meeting

  • 8

    Importance of standardizing body composition outcomes in future studies.

Original Source(s)

Incretin Trials Often Exceed Muscle-Loss Benchmarks

  • by Kerri Miller

  • April 17, 2026

Related Content

ACP Updates Breast Cancer Screening Guidance

Biennial mammography recommended for ages 50 to 74 years, with shared decision-making outside that range.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

FURL vs Mini-PCNL in 2 to 3 cm Stones

Review reports comparable stone-free rates with suction-assisted ureteroscopy